Description
P.18 Daratumumab therapy in patients with immunoglobulin light chain amyloidosis, a single center experience
- You cannot add another "Article: Clinically meaningful survival benefit with atezolizumab + nab-paclitaxel in previously untreated patients with PD-L1+ metastatic triple negative breast cancer" to your cart. View cart
Article: P.18 Daratumumab therapy in patients with immunoglobulin light chain amyloidosis, a single center experience
€3.03
Related products
-
Article: Highlights in genitourinary cancers
€3.03 Add to cart -
Article: Highlights in breast cancer
€3.03 Add to cart -
Article: Highlights in respiratory oncology
€3.03 Add to cart -
Article: Updated results of the phase III COLUMBUS trial further solidify BRAF/MEK combinations as standard of care for BRAF-mutated advanced melanoma
€3.03 Add to cart
